See what Medtronic, Guardant, and Acutus were up to this time last year.

Katie Hobbins, Managing Editor

January 19, 2023

1 Min Read
calendar (1).jpg
Image courtesy of Brian Jackson / Alamy Stock Photo

Medtronic Touts 'Highly Encouraging' Data for Lower-Energy SCS Therapy

The three-month results show meaningful pain relief using a lower-energy variation of the company's Differential Target Multiplexed Spinal Cord Stimulation therapy.

Guardant Enrolls Ist Patient in SHIELD Lung Study

Data from the lung cancer blood test will support a PMA submission.

Acutus to Reduce Workforce in Restructuring Plan

The company is taking the measure because of COVID-related challenges including hospital access constraints and staffing shortages.

How Hyperfine Developed the World's First Portable MRI Machine

Hyperfine CEO Dave Scott talks candidly about what it takes to bring a disruptive technology to market, and the clinical impact that the Swoop portable MRI machine is already having.

Intuitive Beats Expectations Despite COVID-19 Challenges

The surgical robotics pioneer managed to triumph in earnings even though there were procedure disruptions.

About the Author(s)

Katie Hobbins

Managing Editor, MD+DI

Katie Hobbins is managing editor for MD+DI and joined the team in July 2022. She boasts multiple previous editorial roles in print and multimedia medical journalism, including dermatology, medical aesthetics, and pediatric medicine. She graduated from Cleveland State University in 2018 with a bachelor's degree in journalism and promotional communications. She enjoys yoga, hand embroidery, and anything DIY. You can reach her at [email protected].

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like